Arrowhead targets rare genetic disorder filing for RNAi after Phase 3 win
Arrowhead Pharmaceuticals’ RNAi treatment has succeeded in a registrational test in patients with an ultra-rare lipid metabolism disorder, bolstering plans for a regulatory filing that follows hot on...
View ArticleStructure's oral GLP-1 produces comparable weight loss to Lilly's oral candidate
Structure Therapeutics’ oral GLP-1 hit all endpoints in a pair of mid-stage studies evaluating weight loss and safety, sending its stock $GPCR up nearly 55% on Monday morning. The drug, dubbed...
View ArticleAgios plans thalassemia filing in US after unveiling data in...
Agios Pharmaceuticals’ stock $AGIO jumped more than 19% on Monday morning after the company announced its oral candidate for the blood disorder thalassemia reduced patients’ need for transfusions in a...
View ArticleFauci pushes back on pandemic criticisms before divided House panel
Four years after the Covid-19 pandemic began, the nation’s former top infectious disease official Anthony Fauci appeared on Monday before a panel of lawmakers to defend his response to the pandemic....
View ArticleClik here to view.
At ASCO: big readouts, revenue questions, and the ups and downs of ADCs
CHICAGO – More than 40,000 clinicians, biopharma executives, investors, drug salespeople and many others involved in cancer research descended upon McCormick Place in Chicago for the American Society...
View ArticleHow FarmboxRx uses food deliveries to encourage patients to get preventive care
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) FarmboxRx is putting a spin on the usual food-as-medicine programs. The startup, founded in 2014,...
View Article#ASCO24: Sanofi touts Phase 3 Sarclisa data in multiple myeloma as it plays...
Sanofi reported positive Sarclisa data from a registrational test in certain newly-diagnosed multiple myeloma patients, with the company anticipating a US launch as early as this year. The French...
View ArticleIllumina board agrees to spin off Grail rather than sell the cancer...
Illumina’s board has decided to spin out Grail into its own company this month, the DNA sequencing company announced Monday. Since Illumina announced in December that it would unwind its $8 billion...
View ArticleClik here to view.
Australian life sciences VC Brandon Capital raises $180M for sixth fund
Melbourne-based Brandon Capital has secured AUD $270 million ($180 million) to continue seeding life sciences companies in its home country of Australia and New Zealand, and extend its presence into...
View ArticleClik here to view.
Merck KGaA continues AI drug discovery deal spree with Biolojic Design
Merck KGaA has tapped Israel biotech Biolojic Design to help create multi-specific antibodies using AI. In the latest AI-driven collaboration Merck KGaA has announced in the past several months,...
View ArticleStartup raises $25M for cancer drug targets created by alternative RNA splicing
Envisagenics, a startup founded by scientists from Cold Spring Harbor Laboratory, has raised a $25 million series B round to develop drugs for cancer and neurodegenerative disease, the company told...
View ArticleAnnexon proclaims Phase 3 win for complement inhibitor in Guillain-Barré...
Annexon Biosciences reported new Phase 3 data for its Guillain-Barré Syndrome (GBS) drug Tuesday morning, saying the low dose achieved the trial’s primary endpoint. The company has a lot riding on the...
View ArticleBridgeBio spotlights 12 and 18-month data for potential achondroplasia drug...
BridgeBio touted longer-term data for its achondroplasia drug infigratinib from a mid-stage trial on Tuesday, setting the treatment up to be a future competitor for BioMarin’s Voxzogo, the first and...
View ArticleClik here to view.
Bristol Myers' Opdivo-Yervoy combo hits endpoints in Phase 3 early liver...
Bristol Myers Squibb’s Opdivo and Yervoy combo could become the new standard of care in first-line unresectable hepatocellular carcinoma (uHCC) according to Phase 3 data presented at the American...
View ArticleNovo Holdings’ head of Asia on investing in ‘China for China,’ and staying...
Geopolitical headwinds may have given some foreign life sciences investors pause about investing in China. But for Novo Holdings Asia, it’s a good time to double down. The group is finding valuations...
View ArticleWhat the first four participants for FDA's Operation Warp Speed for rare...
FDA’s biologics chief Peter Marks famously coined the first race to the Covid-19 vaccine as Operation Warp Speed. Now the second iteration of OWS is targeting rare diseases, with the FDA officially...
View ArticleVilya raises $21M in Series A extension; Shionogi to build research center in...
Plus, news about Immutep, Eisai and Iterum Therapeutics: Computational biotech extends Series A: Vilya Therapeutics, a startup based in Seattle, added $21 million to its Series A, which it first...
View ArticleViking expands on Phase 2b data for NASH drug, touting histological endpoints
Viking Therapeutics announced Tuesday morning new data from a Phase 2b trial looking at its NASH drug, aiming to provide a fuller picture of the results before beginning a pivotal study. The biotech...
View ArticleUK's NICE recommends Lilly's Zepbound for weight loss
The UK’s National Institute for Health and Care Excellence (NICE), which advises the National Health Service on which drugs to cover, released new draft guidance on Tuesday recommending the use of Eli...
View ArticleHouse lawmakers float transparency reforms for 340B program at hearing
WASHINGTON – House lawmakers on Tuesday floated reforms to a controversial drug discount program serving low-income populations, but it’s still unclear which policies will come to fruition and how. The...
View Article